Health
Pharmaceutical Industry Faces Trials Pauses and Price Controversies
Novartis and Bristol Myers Squibb have paused multiple cell therapy trials, while a $480,000 cancer drug has become routine. Read the latest pharma headlines in today's STAT+.
Coverage timeline — 1 article
STAT News
Novartis and Bristol Myers Squibb have paused multiple cell therapy trials, while $480,000 has now become a routine price for a cancer drug. Read the latest pharma headlines in today's…
2026-09-01 13:21 UTC